Li-Fraumeni syndrome: Update, new data and guidelines for clinical management;Le syndrome de Li-Fraumeni: Mise au point, données nouvelles et recommandations pour la prise en charge

Bulletin du Cancer

Volumn 88, Issue 6, 2001, Pages 581-587

  Frebourg, T ^a   Abel, A ^a   Bonaiti Pellie, C ^a   Brugieres L ^a   Berthet, P ^a   Bressac De Paillerets, B ^a   Chevrier, A ^a   Chompret, A ^a   Cohen Haguenauer, O ^a   Delattre, O ^a   Feingold, J ^a   Feunteun, J ^a   Frappaz, D ^a   Fricker, J P ^a   Gesta, P ^a   Jonveaux, P ^a   Kalifa, C ^a   Lasset, C ^a   Leheup, B ^a   Limacher, J M ^a   Longy, M ^a   Nogues, C ^a   Oppenheim, D ^a   Sommelet, D ^a   Soubrier, F ^a   Stoll, C ^a   Stoppa Lyonnet, D ^a   Tristant, H ^a   more..

^a INSERM   (France)

Author keywords

Li Fraumeni syndrome

Indexed keywords

PROTEIN DERIVATIVE; TRANSCRIPTION FACTOR;

APOPTOSIS; CANCER RISK; CANCER SCREENING; CELL CYCLE; DNA DAMAGE; FAMILIAL CANCER; GENE MUTATION; GENETIC COUNSELING; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE;

ADULT; AGE FACTORS; CHILD; FEMALE; GENE SILENCING; GENES, P53; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LI-FRAUMENI SYNDROME; MALE; MAMMOGRAPHY; MUTATION; PHOSPHORYLATION; PRACTICE GUIDELINES; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES;

EID: 0034905435     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Soft-tissue sarcomas, breast cancers and other neoplasms: A familial syndrome?
2. Rhaddomyosarcoma in children; epidemiologic study and identification of a familial cancer syndrome
3. A cancer family syndrome in twenty-four kindreds
4. Multiple primary cancers in families with Li-Fraumeni syndrome
5. Li-Fraumeni syndrome: A molecular and clinical review
6. Screening for germ line p53 mutations in children with malignant tumors and a family history of cancer
7. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families
8. Germline mutations in the TP53 gene
9. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms
10. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome
11. Two Li-Fraumeni syndrome families with novel germline p53 mutations: Loss of the wild-type p53 allele in only 50% of tumours
12. Chromosome instability is a predominant trait of fibroblasts from Li-Fraumeni families
13. DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation
14. A possible screening test for inherited p53-related defects based on the apoptotic response of peripheral blood lymphocytes to DNA damage
15. Retention of wild-type p53 in tumors from p53 heterozygous mice: Reduction of p53 dosage can promote cancer formation
16. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein
17. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
18. Tumor spectrum analysis in p53-mutant mice
19. Are there low-penetrance TP53 alleles? Evidence from childhood adrenocortical tumors
20. P53 germline mutations in childhood cancers and cancer risk for carrier individuals
21. Le gène suppresseur de tumeurs TP53: Vingt ans (et dix mille mutations) après
22. A simple p53 functional assay for screening cell lines, blood, and tumors
23. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome
24. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase
25. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway
26. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites
27. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53
28. DNA damage-induced activation of p53 by the checkpoint kinase Chk2
29. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: Preliminary results
30. Sensitivity and predictive value of criteria for p53 germline mutation screening
31. Screening hCHK2 for mutations
32. Detection of 11 germline inactivating TP53 mutations and absence of TP63 and CHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome